Who Owns EirGenix Company?

EirGenix Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns EirGenix?

Understanding a company's ownership is fundamental to grasping its strategic moves and future prospects. EirGenix, a prominent player in the biologics CDMO space, has seen its ownership landscape evolve since its 2012 founding in Taiwan. This exploration dives deep into the EirGenix SWOT Analysis, examining the key players who have shaped its journey from its inception to its current position as a global force.

From its initial investors to its current shareholders, unraveling the EirGenix ownership structure reveals critical insights into its operational influence and long-term vision. Knowing who owns EirGenix provides a clearer picture of the company's direction, its commitment to innovation, and its ability to navigate the competitive landscape. This analysis will cover EirGenix's company profile, including its major shareholders list and the influence of the EirGenix management team.

The foundation of EirGenix, officially established on December 21, 2012, involved key partnerships that shaped its early ownership structure. A pivotal joint venture agreement signed in March 2013 with Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB) set the stage for EirGenix's operational capabilities.

This agreement allowed EirGenix to acquire the DCB's cGMP biopharmaceutical pilot plant facility in April 2013. This strategic move provided immediate access to crucial resources and expertise. This early acquisition was critical in establishing EirGenix's operational framework.

Dr. Lee-Cheng Liu, identified as the Founder, Chairman, and President, played a central role in the early vision of the company. His goal was to establish a Contract Development and Manufacturing Organization (CDMO) focused on technology. This vision was backed early on by Formosa Laboratories, which held a 20% ownership stake.

Founding Date

EirGenix was officially founded on December 21, 2012, marking the beginning of its journey in the biopharmaceutical industry.

Key Partnership

The joint venture agreement signed in March 2013 with Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB) was a significant milestone.

Facility Acquisition

In April 2013, EirGenix acquired the DCB's cGMP biopharmaceutical pilot plant facility, providing access to crucial resources.

Founder's Vision

Dr. Lee-Cheng Liu, the Founder, Chairman, and President, envisioned EirGenix as a technology-focused CDMO.

Early Backer

Formosa Laboratories held a 20% ownership stake early on, supporting EirGenix's vision for global expansion.

Public-Private Collaboration

The transfer of the DCB facility highlighted a public-private collaboration model in EirGenix's early structure.

The early ownership structure of EirGenix, including the roles of key shareholders and the company's financial backers, reflects a strategic approach to growth. The acquisition of the DCB facility and the backing from Formosa Laboratories were critical steps. For more information on the company's strategic direction, you can refer to the Growth Strategy of EirGenix. Further details on EirGenix shareholders and the company's ownership structure can be found in public filings and investor relations materials. Understanding who owns EirGenix is key to assessing its long-term prospects.

EirGenix SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of EirGenix has undergone significant changes, particularly with its initial public offering (IPO) and subsequent investments. The company went public on the Taipei Exchange (TPEx) on June 28, 2019, under the stock code 6589, with a listing price of 30.85 New Taiwan Dollars. This IPO was a pivotal moment, transforming EirGenix from a private entity to a publicly traded company. As of May 29, 2025, EirGenix's market capitalization reached 19.02 billion TWD.

A key development in EirGenix's ownership occurred in April 2021. Terry Gou, the founder of Foxconn, announced his intention to become the largest shareholder. Through Hung Wei Co., Gou's company, an agreement was made to acquire an 18.56% stake in EirGenix for NT$5.03 billion (approximately US$177 million). This investment involved Hung Wei acquiring 55 million new shares through a private placement at NT$91.5 per share, a plan that required shareholder approval and would be carried out in stages. This strategic investment aimed to boost EirGenix's global expansion.

EirGenix has raised a total of $480 million through various funding rounds, including seed and later-stage VC investments. The company also had an IPO announced for December 27, 2024, indicating ongoing shifts in its financing status. For more insights, check out the Marketing Strategy of EirGenix.

EirGenix Ownership Overview

EirGenix's ownership structure is diverse, involving individual insiders, venture capital firms, institutional investors, and private and public companies.

• The company went public in 2019, which significantly impacted its ownership.
• Terry Gou's investment in 2021 aimed to boost global expansion.
• The National Development Fund is listed as a major shareholder.
• EirGenix has raised substantial funds through various investment rounds.

EirGenix PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Understanding the governance of EirGenix involves examining its Board of Directors and how they influence the company's direction. While comprehensive details on all board members and their affiliations aren't fully available in public records from 2024-2025, key figures are known. Dr. Lee-Cheng Liu, as Founder, Chairman, and President, holds a significant leadership role. Other important executives include Dr. Chih-Jung Chang, Senior Vice President and CEO of Biomanufacturing; Dr. Thomas Schulze, Managing Director of EirGenix Europe GmbH; Dr. Shang-Chung Ju, Executive Director and Chief Engineer; Dr. Irene, Ae-Ning Lin, Executive Director overseeing CMCS and Research & Development; and Hsiu-Chuan Yang, the Chief Financial Officer, Vice President, and Manager of Corporate Governance. These individuals collectively shape the strategic decisions and operational oversight of the company.

The board's composition and the roles of these executives are crucial for understanding the company's operational and strategic focus. The presence of the founder at the helm, along with experienced leaders in key operational areas, indicates a blend of founder-driven vision and operational expertise. This structure is vital for investors seeking to understand the dynamics of EirGenix's Competitors Landscape and its strategic positioning within the biotech industry. The board's decisions directly impact the company's ability to navigate market challenges and capitalize on opportunities.

EirGenix's voting structure typically follows a one-share-one-vote principle for common stock. In the 2024 Annual Shareholders' Meeting, a significant majority, with 98.14% of the votes cast, supported the proposals. This demonstrates a standard voting mechanism. Furthermore, the company's practices, as outlined in the 2024 Annual Shareholders' Meeting Minutes, address aspects like restricted stock awards. Employees holding these awards have the same voting rights and dividend entitlements as common stockholders, even during the vesting period. This structure supports equitable shareholder rights, which is a key factor for EirGenix shareholders and potential EirGenix investors.

EirGenix Ownership Insights

The Board of Directors at EirGenix plays a crucial role in the company's governance. Key figures include Dr. Lee-Cheng Liu, Dr. Chih-Jung Chang, and others. The voting structure follows a one-share-one-vote principle.

• Dr. Lee-Cheng Liu serves as the Founder, Chairman, and President.
• Voting structure follows a one-share-one-vote principle.
• The company's Articles of Incorporation address restricted stock awards.
• Private placements, like Terry Gou's investment, have specific resale restrictions.

EirGenix Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, significant shifts have occurred in the ownership structure of EirGenix. A pivotal moment was the investment by Terry Gou, founder of Foxconn, in April 2021. Through his company, Hung Wei Co., Gou aimed to acquire an 18.56% stake via a private placement of approximately NT$5.03 billion (US$177 million). This strategic move positioned Gou as the largest shareholder, signaling a commitment to accelerate EirGenix's global expansion. This type of investment highlights a trend of cross-industry collaboration in the biopharmaceutical sector, particularly in Asia. Understanding who owns EirGenix is key to assessing its strategic direction.

Another critical development is EirGenix's ongoing IPO registration, with an announced IPO date of December 27, 2024. This initiative aims to raise capital and broaden its public shareholder base, building on its initial listing on the Taipei Exchange in June 2019. The company has already secured approximately $480 million in funding, demonstrating strong venture capital backing. For those seeking detailed information, exploring the Brief History of EirGenix provides additional context on its evolution and ownership.

The biopharmaceutical CDMO market, where EirGenix operates, is experiencing robust growth. The Antibody Drug Conjugates (ADC) Contract Manufacturing Market, for example, grew from USD 11.88 billion in 2023 to USD 13.06 billion in 2024, with a projected CAGR of 11.82% to reach USD 25.99 billion by 2030. This expansion is driven by factors such as increased cancer prevalence, innovations in linker technology, and rising R&D investments. As a key player, EirGenix is well-positioned to capitalize on these trends, potentially leading to further capital infusions, strategic partnerships, or industry consolidation. The company's proactive approach to exploring M&A opportunities and establishing co-development alliances with international partners could further shape its ownership and strategic partnerships. The EirGenix shareholders are poised to benefit from these developments.

Key Development

Terry Gou's investment in 2021 significantly impacted EirGenix's ownership structure, making him the largest shareholder.

IPO Plans

EirGenix's IPO registration, with a planned date of December 27, 2024, aims to raise capital and broaden its shareholder base.

Market Growth

The biopharmaceutical CDMO market, especially ADC, is expanding, offering opportunities for EirGenix.

Strategic Alliances

EirGenix is actively pursuing M&A and co-development alliances to strengthen its market position and potentially influence its ownership.

EirGenix Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs